Change in number of shares in BioGaia AB

Redemption of warrants during May has led to an increase of BioGaia's share capital by SEK 3,000 to a total of SEK 17,210,562. The number of shares has increased by 3,000 B shares to a total of 740,668 A shares and 16,469,894 B shares which is equal to 23,876,574 votes.

In June 2007, BioGaia carried out a warrant programme approved by the AGM the same year. A total of 128 950 options were subscribed for by the employees (of which 27 000 by the management). Each warrant grants the holder the right to subscribe for one class B share for SEK 76.70 during the period from 15 May 2010 to 31 August 2010.

For additional information contact:

Peter Rothschild, President, telephone: +46 8 -555 293 00

Margareta Hagman, Executive Vice President, telephone: +46 8-555 293 00

Latest press releases from BioGaia:

2010-05-10              New Reuteri study published: L. reuteri Protectis reduced gastrointestinal symptoms and hospital stay in premature newborns

2010-05-07              Annual General Meeting of BioGaia

2010-05-06              BioGaia AB Interim Report 1 January - 31 March 2010

BioGaia is a biotechnology company that develops, markets and sells probiotic products
with documented health benefits. The products are primarily based on the lactic acid
bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects.
The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm.

www.biogaia.com

I

View as pdf: Press relese May 26,2010.pdf